https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-28 / Immunotherapy 2015;7(8):855-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-28 / Immunotherapy 2015;7(8):855-602015-05-28 00:00:002021-11-16 07:55:05Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-07 / Cell Death Dis 2015 May;6:e1758
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-07 / Cell Death Dis 2015 May;6:e17582015-05-07 00:00:002019-02-15 09:22:47IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-01 / Cell Oncol (Dordr) 2015 Aug;38(4):279-88
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-01 / Cell Oncol (Dordr) 2015 Aug;38(4):279-882015-05-01 00:00:002015-05-01 00:00:00Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-16 / Tumour Biol. 2015 Sep;36(9):7121-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-16 / Tumour Biol. 2015 Sep;36(9):7121-312015-04-16 00:00:002019-02-15 09:22:44Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-12 / Cancer Biother. Radiopharm. 2015 May;30(4):182-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-12 / Cancer Biother. Radiopharm. 2015 May;30(4):182-62015-03-12 00:00:002019-02-15 09:22:46Transplanted tumor growth and the incidence of T-lymphocyte populations in the spleen of newcastle virus-treated mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-11 / Mol. Cancer Ther. 2015 May;14(5):1247-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-11 / Mol. Cancer Ther. 2015 May;14(5):1247-582015-03-11 00:00:002019-02-15 09:22:43Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-02 / Biomed Res Int 2015;2015:127828
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-02 / Biomed Res Int 2015;2015:1278282015-03-02 00:00:002015-03-02 00:00:00Inhibitory and apoptosis-inducing effects of Newcastle disease virus strain AF2240 on mammary carcinoma cell line
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-01 / Mol. Biol. (Mosk.) 2015 Mar-Apr;49(2):195-204
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-01 / Mol. Biol. (Mosk.) 2015 Mar-Apr;49(2):195-2042015-03-01 00:00:002019-02-15 09:22:42[Expressing foreign genes by Newcastle disease virus for cancer therapy]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-15 / J Cancer 2015;6(3):203-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-15 / J Cancer 2015;6(3):203-172015-01-15 00:00:002021-11-15 13:29:28Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-01 / Drugs Future 2015;40(11):739-749
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-01 / Drugs Future 2015;40(11):739-7492015-01-01 00:00:002019-02-15 09:00:22EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA
